<DOC>
	<DOCNO>NCT00738452</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-ray kill tumor cell . Drugs use chemotherapy , carboplatin , paclitaxel , cisplatin , etoposide , work different way stop growth tumor cell , either kill cell stop dividing . Radiolabeled monoclonal antibody find tumor cell carry tumor-killing substance without harm normal cell . Giving radiation therapy combination chemotherapy together radiolabeled monoclonal antibody therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose radiolabeled monoclonal antibody therapy give radiation therapy combination chemotherapy treat patient stag I-IIIB non-small cell lung cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion Radiation Therapy Alone Combined Radiation Therapy Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) associate toxicity intravenous yttrium-90 ( 90Y ) chimeric T84.66 ( cT84.66 ) anti-carcinoembryonic antigen ( CEA ) antibody target radiotherapy deliver carboplatin/paclitaxel cisplatin/etoposide external beam radiotherapy patient CEA positive stage III unresectable medically inoperable non-small cell lung cancer . SECONDARY OBJECTIVES : I . To collect data biodistribution , clearance metabolism 90Y ( yttrium-90 ) 111In ( indium-111 ) chimeric T84.66 administer intravenously . II . To collect data radiation dose whole body , normal organ , tumor serial nuclear imaging . OUTLINE : This dose-escalation study yttrium Y 90 anti-CEA monoclonal antibody cT84.66 . CHEMORADIOTHERAPY : Patients undergo external beam radiation therapy 5 day week 45 day . Beginning within 24 hour start radiation therapy , patient receive paclitaxel intravenously ( IV ) 1 hour carboplatin IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 OR cisplatin IV 60 minute day 1 , 8 , 29 , 36 etoposide IV 60 minute day 1-5 29-33 . CONSOLIDATION RADIOIMMUNOTHERAPY : Beginning 6-10 week completion chemoradiotherapy , patient stable disease , partial response , complete response receive therapeutic dose yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 month</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Patients must &gt; = 18 year age . Patients must Karnofsky performance status &gt; = 60 % . Patients must histological confirmation nonsmall cell lung cancer must tumors produce CEA document either immunohistochemistry elevate serum CEA level . Patients must American Joint Committee Cancer ( AJCC ) Version 7 Stage IIIIB non small cell lung cancer ( NSCLC ) surgical candidate due unresectability medical inoperability . Patients must undergo radiation therapy alone , radiation therapy plus systemic therapy ( include chemotherapy tyrosine kinase inhibitor ) treatment lung cancer ; patient may receive two cycle consolidative chemotherapy radiation therapy +/ chemotherapy ; therapy must complete within 612 week prior start treatment trial . Patients must measurable evaluable disease prior receive standard radiation therapy alone , radiation therapy plus systemic therapy . Patients must evidence progressive disease ( therefore , must stable disease , partial response complete response ) therapy give prior enrollment study . No radiotherapy , immunotherapy , chemotherapy within last 5 year prior diagnosis locally advanced NSCLC ; prior adjuvant chemotherapy tyrosine kinase inhibitor therapy early stage , resect NSCLC allow long give &gt; 12 month prior current diagnosis locally advance NSCLC . Patients must demonstrate forced expiratory volume one second ( FEV1 ) &gt; = 0.9 . Adequate bone marrow function evidence hemoglobin &gt; = 10 gm % , WBC &gt; = 3500/ul , absolute granulocyte count &gt; = 1,500/mm3 , platelet &gt; = 140,000/ul . Patients may transfuse reach hemoglobin &gt; =10 gm % . Patients must total bilirubin &lt; = 1.5 mg/dL liver transaminases high 2 time upper limit normal . Patients must serum creatinine &lt; = 1.5 x upper limit normal ( ULN ) creatinine clearance &gt; = 45 cc/min ( base Cockcroft Gault formula ) . Patients must postobstructive pneumonia serious infection . If patient previously receive murine chimeric antibody , serum antiantibody test must negative . Serum HIV test hepatitis B surface antigen hepatitis C antibody test must negative . Women childbearing potential must negative serum pregnancy test prior entry study must practice effective form contraception . Patients nonmalignant intercurrent illness ( example cardiovascular , pulmonary , central nervous system disease ) either poorly control currently available treatment severity investigator deem unwise enter patient protocol shall ineligible . Metastatic disease . Malignant pleural effusion . Patients receive least 50 Gy thoracic radiation course radiation +/ systemic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>